SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Progesterone Formulation

Version 1.0  Revision Date: 10/17/2019  SDS Number: 5173797-00001  Date of last issue: -
Date of first issue: 17.10.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Progesterone Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Innishannon
County Cork - Ireland
Telephone : 353 214329300
Telefax : 908-735-1496
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Carcinogenicity, Category 2 H351: Suspected of causing cancer.
Reproductive toxicity, Category 1A H360: May damage fertility or the unborn child.
Effects on or via lactation H362: May cause harm to breast-fed children.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms :

Signal word : Danger
Hazard statements :
H351  Suspected of causing cancer.
H360  May damage fertility or the unborn child.
H362  May cause harm to breast-fed children.

Precautionary statements :
Prevention:
P201 Obtain special instructions before use.
Progesterone Formulation

Hazardous components which must be listed on the label:
Progestrone

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 27.777 %

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture if dispersed.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progesterone</td>
<td>57-83-0 200-350-6</td>
<td>Carc. 2; H351 Repr. 1A; H360 Lact. H362</td>
<td>27.777</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty
of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Suspected of causing cancer.
May damage fertility or the unborn child.
May cause harm to breast-fed children.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: High volume water jet

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Do not use a solid water stream as it may scatter and spread fire.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment: In the event of fire, wear self-contained breathing apparatus.
for firefighters

Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions:
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Occupational Exposure Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
</tr>
<tr>
<td>Progesterone</td>
</tr>
<tr>
<td>Further information</td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>56 mg/m³</td>
</tr>
</tbody>
</table>
Progesterone Formulation

8.2 Exposure controls

Engineering measures
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material
- Chemical-resistant gloves

Remarks
- Consider double gloving.

Skin and body protection
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type
- Combined particulates and organic vapour type (A-P)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Progesterone Formulation

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Crystalline powder</td>
</tr>
<tr>
<td>Colour</td>
<td>white to off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>odourless</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>126 °C</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>practically insoluble</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
</tbody>
</table>

9.2 Other information

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Progesterone Formulation

Version 1.0
Revision Date: 10/17/2019
SDS Number: 5173797-00001
Date of last issue: -
Date of first issue: 17.10.2019

Particle size: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Dust can form an explosive mixture in air. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Progesterone:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Progestosterone Formulation

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Progestosterone:
Genotoxicity in vitro : Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Method: OECD Test Guideline 482
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Monkey
Application Route: Subcutaneous
Result: negative

Carcinogenicity
Suspected of causing cancer.

Components:

Progestosterone:
Species : Mouse
Application Route: Subcutaneous
Exposure time : 19 weeks
Result : positive

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

Reproductive toxicity
May damage fertility or the unborn child.
May cause harm to breast-fed children.

Components:

Progestosterone:
Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Result: positive

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Skin contact
Result: positive

Reproductive toxicity - Assessment : Positive evidence of adverse effects on sexual function, fertility and/or development from human epidemiological studies., Studies indicating a hazard to babies during the lactation period
STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Aspiration toxicity
Not classified based on available information.

SECTION 12: Ecological information

12.1 Toxicity

Components:

Progesterone:

Ecotoxicology Assessment
Acute aquatic toxicity : Toxic effects cannot be excluded
Chronic aquatic toxicity : Toxic effects cannot be excluded

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential

Components:

Progesterone:
Partition coefficient: n-octanol/water : Pow: 3.65

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

If not otherwise specified: Dispose of as unused product.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Progesterone Formulation

The components of this product are reported in the following inventories:
IECSC : not determined
AICS : not determined
DSL : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H351 : Suspected of causing cancer.
H360 : May damage fertility or the unborn child.
H362 : May cause harm to breast-fed children.

Full text of other abbreviations
Carc. : Carcinogenicity
Lact. : Effects on or via lactation
Repr. : Reproductive toxicity

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalu-
Progesterone Formulation

Classification of the mixture:

<table>
<thead>
<tr>
<th>Classification</th>
<th>Code</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carc. 2</td>
<td>H351</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Repr. 1A</td>
<td>H360</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Lact.</td>
<td>H362</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN